In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Related Pages

Childhood Cancer Trial Results

More Chemotherapy May Help after Initial Treatment for Childhood Leukemia Fails
(Posted: 06/07/2012) - A study suggests that at least some children diagnosed with acute lymphoblastic leukemia who respond poorly to initial chemotherapy may do better if they receive additional chemotherapy rather than a stem cell transplant.

Less-Intense Chemo Effective in Children with Intermediate-Risk Neuroblastoma
(Posted: 06/13/2007, Updated: 11/01/2010) - Infants and children with intermediate-risk neuroblastoma who received a less-intensive chemotherapy regimen had three-year overall survival rates as good as those patients in an earlier trial who received treatment that was more intensive and more toxic, according to findings presented at the 2007 ASCO meeting in Chicago.

Addition of immunotherapy boosts pediatric cancer survival:
(Posted: 09/29/2010) - Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years.  The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study in the Sept. 30, 2010, New England Journal of Medicine.

For Children with Leukemia, Radiation May Be Unnecessary
(Posted: 07/23/2009) - Children with the most common form of leukemia can safely forego radiation therapy to prevent relapse if they are treated with chemotherapy regimens tailored to their individual needs, according to the June 25, 2009, New England Journal of Medicine.

Less-Intense Chemotherapy Benefits Some Children With B-Cell Non-Hodgkin Lymphoma
(Posted: 04/25/2007) - Children and adolescents with less advanced B-cell non-Hodgkin lymphoma did just as well, and suffered fewer side effects, when treated with lower doses of multi-drug chemotherapy than is called for by the current standard of care, according to the April 1, 2007, issue of the journal Blood.